What this study is
This randomized phase III trial studies short course vaginal cuff brachytherapy to see how well it works compared with standard of care vaginal cuff brachytherapy in treating participants with stage I-II endometrial cancer. Short course vaginal cuff brachytherapy, also known as internal radiation therapy, uses (over a shorter period) radioactive material placed directly into or near a tumor in the upper portion of the vagina to kill tumor cells.
After completion of cohort 1 (108 participants), the protocol was expended to add a second cohort of 80 additional participants, and re-opened study recruitment.
What's being tested
- Vaginal Cuff Brachytherapy
Intervention · RADIATION
Undergo standard of care vaginal cuff brachytherapy
- Short course vaginal cuff brachytherapy
Intervention · RADIATION
Undergo short course vaginal cuff brachytherapy
Study details
- Official title
- Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer Compared to Standard of Care (SAVE)
- Sponsor
- University of Utah
- Conditions
- Endometrial Clear Cell Adenocarcinoma · Endometrial Endometrioid Adenocarcinoma · Endometrial Serous Adenocarcinoma · Stage I Uterine Corpus Cancer · Stage IA Uterine Corpus Cancer · Stage IB Uterine Corpus Cancer · Stage II Uterine Corpus Cancer · Uterine Corpus Carcinosarcoma · Uterine Corpus Sarcoma
- Enrolling
- 188 people
- Starts
- 2018-02-02
- Est. completion
- 2029-10-31
- Design
- Open-label, randomized, parallel groups, Phase 3
- Record
- View on ClinicalTrials.gov ↗
Who can join
Sex ALLHealthy volunteers Not acceptedYou may qualify if
- Histologically confirmed endometrial carcinoma: endometrioid type, serous, and clear cell, to include tumors originating in the cervix, but are primarily located in the uterus, and for whom vaginal cuff brachytherapy is indicated. Carcinosarcoma and other sarcomas are permitted; Federation of Gynecology and Obstetrics (FIGO) stage I and stage II, with one of the following combinations of stage and grade:; Stage IA, grade 1 with LVSI, 2, 3; Stage IB, grades 1-3; Stage II, grades 1-3; Stage IIIA, grades 1-3, not receiving EBRT as part of adjuvant therapy.
- Participants post-hysterectomy and free from residual disease.
- World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG)-performance status 0-2.
- Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.
- Life expectancy of >2 years.
You can't join if
- Stages of endometrial carcinoma other than described.
- Previous pelvic radiotherapy.
- Concurrent malignancy requiring non-protocol anti-cancer treatment other than surgery.
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (5)
3 openLoyola University Medical Center
Maywood, Illinois, United States
- Carly Quick, RN · Contact708-327-3255Carly.quick@luhs.org
- Lorena Leon · Contact464-220-9395lleon4@luc.edu
- William Small, MD · Principal investigator
RecruitingMD Anderson
Houston, Texas, United States
- Mathew G Geena · Contact713-792-4594geenag@mdanderson.org
- Anuja Jhingran, MD · Principal investigator
RecruitingHuntsman Cancer Institute/University of Utah
Salt Lake City, Utah, United States
- Rachel Kingsford · Contact801-585-0115rachel.kingsford@hci.utah.edu
- Cristina DeCesaris, MD · Principal investigator
RecruitingStanford Cancer Center
Palo Alto, California, United States
CompletedIntermountain Medical Center / LDS Hospital
Salt Lake City, Utah, United States
Completed
Study team
Sponsor
University of Utah
Study ID HCI103841
Principal investigator
Cristina DeCesaris, MD
Huntsman Cancer Institute/ University of Utah
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.